We are live on
!
Find out more
PCM
Polaris Capital Management Portfolio holdings
AUM
$1.06B
1-Year Est. Return
40.82%
This Fund
S&P 500
This Quarter
Est. Return
+2.53%
1 Year Est. Return
+40.82%
3 Year Est. Return
+94.3%
5 Year Est. Return
+113.49%
10 Year Est. Return
+358.47%
AUM
$1.5B
AUM Growth
-$246M
(-14%)
Cap. Flow
-$254M
Cap. Flow
% of AUM
-16.9%
Top 10 Holdings %
Top 10 Hldgs %
41.76%
Holding
95
New
4
Increased
11
Reduced
48
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sabra Healthcare REIT
SBRA
|
+$1.8M |
| 2 |
Phillips Edison & Co
PECO
|
+$1.63M |
| 3 |
Abercrombie & Fitch
ANF
|
+$948K |
| 4 |
V2X
VVX
|
+$590K |
| 5 |
Wabash National
WNC
|
+$330K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Popular Inc
BPOP
|
+$37M |
| 2 |
Linde
LIN
|
+$31.7M |
| 3 |
Vipshop
VIPS
|
+$29.9M |
| 4 |
SW
Smurfit Westrock
SW
|
+$29.6M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$26.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 30.98% |
| 2 | Consumer Discretionary | 18.09% |
| 3 | Healthcare | 16.36% |
| 4 | Materials | 8.67% |
| 5 | Technology | 7.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Supernus Pharmaceuticals
SUPN
$2.77B
| $1.36M | 0.09% |
43,100
| – | – |
|
77
Buckle
BKE
$2.37B
| $1.33M | 0.09% |
29,300
| – | – |
|
78
Carlisle Companies
CSL
$15.4B
| $1.31M | 0.09% |
3,500
| – | – |
|
79
Graphic Packaging
GPK
$3.58B
| $1.24M | 0.08% |
58,700
| – | – |
|
80
Exelixis
EXEL
$13.4B
| $1.16M | 0.08% |
26,300
-15,800
| -38% | -$632K |
|
81
Harmony Biosciences
HRMY
$2.24B
| $1.14M | 0.08% |
36,100
| – | – |
|
82
Winnebago Industries
WGO
$909M
| $1.06M | 0.07% |
36,467
| – | – |
|
|
83
Abercrombie & Fitch
ANF
$5B
| $1.04M | 0.07% |
+12,500
| New | +$948K |
|
84
First Seacoast Bancorp
FSEA
$80.3M
| $1.03M | 0.07% |
90,537
+19,900
| +28% | +$222K |
|
85
Regal Rexnord
RRX
$11.9B
| $984K | 0.07% |
6,789
| – | – |
|
86
Kforce
KFRC
$1.06B
| $942K | 0.06% |
22,894
| – | – |
|
87
Maximus
MMS
$3.1B
| $892K | 0.06% |
12,700
| – | – |
|
88
American Eagle Outfitters
AEO
$3.01B
| $862K | 0.06% |
89,600
+7,200
| +9% | +$77.3K |
|
89
Amphastar Pharmaceuticals
AMPH
$916M
| $806K | 0.05% |
35,100
+4,300
| +14% | +$107K |
|
90
Credicorp
BAP
$30.7B
| $805K | 0.05% |
3,600
| – | – |
|
91
Euronet Worldwide
EEFT
$2.7B
| $547K | 0.04% |
5,400
| – | – |
|
|
CFSB
92
DELISTED
CFSB Bancorp
CFSB
| – | – |
-24,300
| Closed | -$185K |
|
|
XRN
93
Chiron Real Estate Inc
XRN
$477M
| – | – |
-15,320
| Closed | -$670K |
|
|
KE
94
Kimball Electronics
KE
$628M
| – | – |
-15,500
| Closed | -$255K |
|
Similar funds
BGIM
EC
ZIG
MWA
DCP
SFP
PP
ECM
Polaris Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Polaris Capital Management held 95 positions worth $1.5B, down 14% from $1.75B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Polaris Capital Management withdrew a net $254M in Q2 2025, closing 3 positions and reducing 48 holdings. Its most notable exit was Chiron Real Estate Inc, an estimated $670K position sold in full.
By sector, the portfolio is most concentrated in Financials at 31% of assets, up from 28% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Polaris Capital Management opened a new position in Sabra Healthcare REIT worth $1.87M.
- Polaris Capital Management's largest Q2 2025 buy was Sabra Healthcare REIT: 101,400 shares worth $1.87M.
- Polaris Capital Management added most to V2X in Q2 2025, an estimated $590K increase.
- Polaris Capital Management's biggest Q2 2025 reduction was Popular Inc, cutting an estimated $37M.
- Polaris Capital Management fully exited Chiron Real Estate Inc in Q2 2025, selling an estimated $670K.
- Polaris Capital Management's ten largest holdings make up 42% of its $1.5B portfolio in Q2 2025.
- Polaris Capital Management opened 4 new positions and closed 3 in Q2 2025.
- Polaris Capital Management's portfolio value fell 14% quarter-over-quarter to $1.5B.
Based on Polaris Capital Management's 13F filing for Q2 2025, filed 21 Jul 2025.